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Abstract 
A PCR-SSCP approach was used to search for mutations in IL-6 receptor genes in 9 human plasma cell lines (HMCL) and in tumor plasma cells 
from 19 patients with fulminating multiple myeloma, an IL-6-related disease. Whereas no mutation was found in the cytokine receptor homologous 
(CRI-I) domain of IL-6Ra, DNA and RNA polymorphisms in the gp130 CRH domain was detected in tumoral samples as well as in blood samples 
from healthy donors. Finally, mutations in the gp130 critical cytoplasmic domain were found in one HMCL and in tumor plasma cells of one patient. 
Only the mutated allele was expressed in the HMCL. 
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1. Iutroduction 
Human multiple myeloma (MM) is a B-cell neoplasia 
affecting the late stage of B-cell differentiation, i.e. the 
plasma cell. In this disease, interleukin (IL)-6 has been 
shown to be a major growth factor in vitro and in vivo 
[l-3]. Initially, IL-6 was considered to be an autocrine 
growth factor produced by tumor cells themselves 
[ 1,4,5], suggesting that deregulated IL-6 gene expression 
could be the major oncogenic event in this disease. How- 
ever, most groups now agree that the autocrine hypothe- 
sis is limited to only a few myeloma cell lines cultured for 
many years in vitro [6-81, and that, in vivo, IL-6 is pro- 
duced by the tumor environment (bone marrow stromal 
cells [9]), possibly as a result of abnormalities in these 
stromal cells [lo]. Thus, high levels of IL-6 circulate in 
patients with MM in vivo [l 11, the IL-6 receptor is pres- 
ent in various normal cells in vivo and IL-6 is a growth 
factor of these cells [12] (dermal cells, myeloid cells, B 
cells, . ..). However only the tumoral clone emerges by 
using this cytokine as a growth factor. Hypothesis for 
explaining the IL-6 dependent emergence of the tumoral 
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clone in vivo is an abnormal signal mediated by IL-6 
receptor activation. These observations uggest hat the 
IL-6 receptor and/or the IL-6 receptor-mediated 
transduction signal, and/or the function induced by this 
transduction signal (proliferation/differentiation), are 
targets of the oncogenic process. The ILdR belongs to 
the hemopoietic growth factor receptor family [13-l 51, 
and is typically made by the association of two chains 
(the IL-6 binding chain, IL-6Ra and the IL-6 signal- 
transducing chain, gp130) which form the active recep- 
tor. This family of receptors is characterized by a 200 
amino acid extracytoplasmic domain referred to as the 
cytokine receptorhomologous (CRH) domain [15]. Pre- 
vious studies using mutagenesis howed the major role, 
for receptors of IL-2, IL-6, erythropoietin (Epo) and 
growth-hormone (GH), of the CRH domain in binding 
and response to their respective ligands [ 16-211. Yawata 
et al. (1993) demonstrated that the IL-6Ra CRH domain 
is responsible both for the binding of the cytokine and 
the association with gp130 to generate the IL-6 signal. 
For two members of this family, mutations in the CRH 
domain have been shown to be associated with abnormal 
response to growth factors: substitution of any of five 
amino acids for an alanine residue in the CRH domain 
of human growth hormone receptor slightly increases 
affinity for the ligand [21]; erythropoietin receptor 
(EpoR) can be constitutively activated by a single point 
mutation in the CRH domain, converting the residue R 
to C at position 129 [ 191. This was further supported by 
transfection experiments where the mutated Epo-R was 
introduced into Ba/F3 cells, which were subsequently 
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rendered tumorigenic [19]. Moreover, mice infected with 
a recombinant spleen focus-forming retrovirus, in which 
the env gene is replaced by the EpoR cDNA mutated at 
codon 129, develop erythroleukemia [22]. 
In addition to the CRH domain, the transducing 
chains of this hematopoietic growth factor family show 
homologies in a cytoplasmic region proximal to the 
transmembrane domain [23-251. The gp130 first 61 in- 
tracytoplasmic amino acids corresponding to this ho- 
mologous region are sticient to generate the growth 
signal [24]. In contrast to gp130, IL-6Ra, though lacking 
both transmembrane and intracytoplasmic domains, is 
still functional. Soluble IL-6Ra, corresponding only to 
the extracytoplasmic domain, can associate with gp130 
in the presence of IL-6 and mediate its function [26]. 
Accordingly, we investigated the IL-6Ra and gp130 
CRH domains and the 61 cytoplasmic amino acids of 
gp130. We analyzed RNA or DNA using the PCR-SSCP 
method alone or in combination with reverse transcrip- 
tion (RT-PCR-SSCP) and studied variant sequences by 
a direct sequencing technique. 
2. Material and methods 
2.1. Cell lines 
Nine human myeloma cell lines (HMCL) were studied. RPM1 8226 
and U266 HMCL are autonomously growing HMCL obtained 20 years 
ago and purchased by us from the ATCC. The other 7 HMCL, termed 
XG-1 to XG-7, were obtained in our laboratory from patients with 
terminal disease and extramedullary proliferation [271. XG-1 to XG-7 
HMCL are dependent on the addition of IL-6 for in vitro growth. Three 
EBV-infected B-cell lines (EBV-BCL) were used as controls: the CESS 
cell line purchased from ATCC and two other cell lines obtained in our 
laboratory after infection by EBV of peripheral blood lymphocytes 
from healthy donors. 
2.2. Freshly-explanted tumor samples 
Tumoral samples were obtained after informed consent. Eight tu- 
moral samples were obtained from bone marrow of 8 patients with 
medullary involvement only, 9 from peripheral blood of patients with 
plasma cell leukemia and 2 from pleural effitsions. All patients with 
MM had an active disease, and all those with extramedullary prolifer- 
ation were in a terminal stage. 12/19 of these samples contained more 
than 50% of plasma cells. For the others samples, plasma cells repre- 
sented at least 10% of the population. Mononuclear cells were har- 
vested by Ficoll-Hypaque density and kept in liquid nitrogen until use. 
Some of these samples were previously analyzed for P53 and Ras 
mutations [28,29]. 
2.3. Control samples 
Peripheral blood mononuclear cells from 27 healthy donors, ob- 
tained after informed consent, were analyzed. Mononuclear cell frac- 
tions were separated by Ficoll-Hypaque density gradient centrifugation 
and kept in liquid nitrogen until needed. 
2.4. Primers 
Primers used for amplification of ILdR CRH domain were: 
aggtcggtgcagctccacgac (sense) and gacacctcgttctcagctg (antisense) for 
the 6rst step of nested PCR, then gtgcacttgctggtggatg (sense), ggccg- 
gactgttctgaaac (antisense); ggctgtgctcttggtgagg (sense), cccgacac- 
tactggcgacgca (antisense); tgcgtcgccagtagtgtcggg (sense), gttccag- 
gagtgggggtcttgc (antisense); cccgctggctcagtgtcacctg (sense), 
ggccgctccaggcgtcgtgg (antisense); cacaacatggatggtcaagg (sense), 
gattctgtccaaggcgtg (antisense). The gp130 CRH domain was amplified 
by using the primers cagaacagcatccagtgtcacc (sense) and cca- 
gaaacttggtgctttagatgg (antisense) for the first step of nested PCR, then 
cttacattcggacagcttgaacag (sense), cttgtgtgttgcccattcag (antisense); 
ggaagggaaacacacttggag (sense), gggcttcactttatatacagg (antisense); 
cctgtatataaagtgaagccc (sense), ggatgctgtgtcttcaggagg (antisense); 
cctcctgaagacacagcatcc (sense), cataggtgatcccacttgc (antisense). And, 
gp130 critical cytoplasmic domain was amp&d by using the primers 
cttctgggagtgctgttctgc (sense), ccacaacacttacatcagtg (antisense); ctca- 
cactcctccaaggcac (sense), caataccactgctgtgtccttc (antisense). 
2.5. RNA preparation and cDNA synthesb 
Frozen cells were disrupted in guanidium thiocyanate solution (4 M 
guanidium thiocyanate; 25 mM trisodium citrate, pH 7; 0.5% sarcosyl; 
0.1 M 2-mercaptoethanol) by drawing the lysate through a 23-gauge 
needle. RNA was pelleted by ultracentrifugation of the homogenate 
over a cesium chloride gradient (5.7 M CsCl, 100 mM EDTA). The 
pellet was ethanol-precipitated with 3 M sodium acetate and resus- 
pended in water. cDNA was synthesized with 2pg of total cellular RNA 
and 500 ng of oligo(dT) primer using the Reverse Transcription System 
PCR-related kit @omega) according to the manufacturer’s recommen- 
dations. 
2.6. DNA extraction 
Cells were lvsed in 0.3 M lithium acetate. 1 mM EDTA (DH 8). 10 
mM Tris pH 8 and 2% SDS. DNA was phenol/chloroform~xtracted 
and ethanol-precipitated before being resuspended in 10 mM Tris, 1 
mM EDTA (PH 8). 
2.7. PCR ampltfication 
Nested oligonucleotide amplification was performed for CRH do- 
main analysis. Two ~1 of reverse transcription products were initially 
amnlnied for 30 cvcles in a final volume of 25 ul containing 10 mM 
Tris-HCl @H 8), i.5 mM MgCl,, 50 mM KCl, d.Ol% gelatin, 100 PM 
dNTPs, 20 pmol of each primer and 1.5 U of Taq polymerase (Perkin- 
Elmer Cetus). A 2 ~1 aliquot of this amplified mixture was used for a 
second round of PCR (30 cycles), with oligonucleotide primers internal 
to the original primers, in the same conditions plus 3 PCi of [a- 
‘*P]dCTP. 
For intracytoplasmic domain analysis, 2 ~1 of reverse transcription 
products or 100 ng of DNA were amplified in the same conditions with 
3 PCi of [a-‘*P]dCTP. 
2.8. SSCP analysis 
An aliquot of the radiolabeled amplification products was diluted 
fivefold in 0.1 I SDS, 10 mM EDTA. Four ~1 of this solution was then 
mixed with 7 ~1 of 95% formamide, 10 mM EDTA, Bromophenol blue 
and xylene cyanol, heated at 90°C for 3 min, chilled on ice and loaded 
(4 PYlane) onto a nondenaturing polyacrylamide gel (6% acrylamide, 
1 x TBE). Electrophoresis was performed in a cold room at 18 W for 
7-8 h. Alternatively, 5% glycerol was added to the gel mix and electro- 
phoresis was carried out at room temperature. The gels were exposed 
to Kodak XAR-5 film at -80°C using an intensifying screen. 
2.9. Direct sequencing 
Shifted SSCP bands were excised from the gel and eluted in 50 ~1 of 
sterile water for 2 h at 65’C. Four ~1 of the eluate was subjected to a 
further round of PCR amplification, then washed using a Centricon 30 
column (Amicon) and sequenced using the Sequenase version 2.0 kit 
(USB). Conditions were according to the manufacturer’s recommenda- 
tions. Sequences were determined on both strands. 
3. Results 
3.1. Luck of mutation in the IL-6Ra CRH domain 
A SSCP analysis can detect mutations in DNA frag- 
ments of less than 200 bp, the 630 bp IL-6R CRH do- 
main was subdivided using 5 overlapping primer pairs. 
With the RT-PCR-SSCP approach, mutations were 
found in some samples but not reproducibly in different 
reverse-transcripts of the same RNA samples, which sug- 
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Fig. 1. PCR SSCP analysis of the gp130 CRH domain. Amplified RT 
fragments from aa 106 to 168 were denatured by heating, and electro- 
phoresis was performed in 6% polyacrylamide gel at a constant 18 W. 
The right hand side lane shows double-strand migration. The arrow- 
heads point to the aberrantly migrating fragments. (a) gel running in 
the cold room; (b) gel running at room temperature with 5% glycerol. 
gest that these mutations were induced by reverse tran- 
scriptase. As all the mutations were found between 
amino acids (aa) 221 and 258, we chose a new primer pair 
enclosing this region and usable on DNA. With this 
approach, no mutations of the IL-6R CRH domain were 
identified in the 9 HMCL and 19 tumor samples ana- 
lyzed. 
3.2. No mutation but sequence polymorphism in the gp130 
CRH domain 
The gp130 CRH domain was analyzed by PCR-SSCP 
from RT-RNA. Nested PCR was used in this approach 
as well, and the CRH domain was subdivided using 4 
overlapping primer pairs. Bands shifts were found only 
in the fragment spanning from aa 106 to 168. As illus- 
trated in Fig. 1, two different mobility shifts were found 
(a) codon 148 
mut wt 
ACGTACGT 
upon SSCP analysis. Determination of the nucleotide 
sequence revealed that these two mobility band shifts 
were due to a substitution leading to a non-conservative 
amino acid change at position 148, replacing Gly with 
Arg (GGT to CGT) in the first case (Fig. 2a), and to a 
conservative A to G transition within codon 122 for the 
second shift (Fig. 2b). Substitution 148 was found in 5 
of the 9 HMCL and 6 of the 19 MM samples analyzed. 
Substitution 122 was found in 1 HMCL and 5 MM 
samples. The systematic nature of these changes sug- 
gested to us that they could in fact be due to a sequence 
polymorphism. In order to prove that these substitutions 
were indeed the result of DNA polymorphism, we stud- 
ied 3 EBV-infected B-cell lines and 27 healthy donors’ 
peripheral blood lymphocytes were analyzed. This analy- 
sis revealed substitution 148 in one EBV cell line and in 
9 healthy donors’ peripheral blood lymphocytes, 
whereas 1 EBV cell line presented substitution 122. Inter- 
estingly in the population presently studied we did not 
detect any sample homozygous for the aa or 148 
polymorphisms. This can most probably be related to the 
rather small size of the population studied and to the 
relative low frequency of these polymorphisms (6 and 
18%, respectively, for the positions 122 and 148). 
3.3. Mutations in the intracytoplasmic domain of gp130 
The intracytoplasmic domain of gp130 was investi- 
gated from DNA since there is no intron in this region. 
The same samples were analyzed as for the gp130 CRH 
domain. Our aim was to determine whether there were 
mutations in the first 61 aa located closest to the trans- 
membrane domain. The primers used covered the first 87 
intracytoplasmic aa which were divided into two over- 
lapping fragments. In this region, one HMCL (U266) 
and one myeloma sample showed band shifts (Fig. 3). 
The U266 cell line presented a C-to-T substitution at 
codon 710, converting Ser to Leu (Fig. 4a). This muta- 
tion affected the 69th intracytoplasmic aa and was thus 
downstream from the first 61 aa near the transmembrane 
domain. Patient Mi presented 5 mutations in this region: 
one conservative nucleotide substitution at codon 711 
(b) codon 122 
mut wt 
ACGTACGT 
Fig. 2. gp130 polymorphism detected by PCR-amplified fragments. Each substitution shown is matched to a control RT (‘mut’ for mutated and ‘wt’ 
for wild type) The codon at which substitution occurs is indicated. Each sequence is shown 5’ (bottom) to 3’ (top). The nucleotide sites of mutation 
are indicated by underlined letters. Arrowheads point to bands corresponding to mutated bases. (a) sequence of band shift obtained from SSCP gel 
running in the cold room; (b) sequence of band shift obtained from SSCP gel running at room temperature with glycerol. 
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Fig. 3. SSCP analysis of the gp130 cytoplasmic domain. Amplified 
fragments from aa 668 to 729 were run on a 6% polyacrylamide gel in 
the cold room. Each lane is identified by the name of the sample 
analyzed, ‘wt’ (wild type) indicates a non-mutated control and ‘ds’ 
(double strand) corresponds to an undenatured sample. Arrowheads 
point to band shifts. (a) SSCP analysis from DNA, (b) SSCP analysis 
from RT. 
(TTG to TTA) and 4 nonconservative substitutions con- 
verting Ser to Ala (TCA to GCA), Ser to Gly (AGT to 
GGT), Val to Phe (GTT to ITT) and Pro to Ala (CCA 
to GCA) at codons 678, 692, 693 and 705 respectively 
(Fig. 4b). U266, like the myeloma sample, presented the 
wild-type allelle and the mutated fragment. On the basis 
of these results, we analyzed this region from RT-RNA. 
As illustrated in Figure 3, the two alleles were expressed 
in patient Mi’s bone marrow myeloma sample, while 
only the mutated allele was expressed in the U266 cell 
line. No mutations were found in DNA samples of the 
3 EBV-infected B-cell lines and the 27 healthy donors’ 
peripheral blood lymphocytes analyzed. 
4. Discussion 
In the present study we analyzed 18 MM and 9 HMCL 
by PCR-SSCP for the presence of point mutations in the 
genes coding IL-6Ra and gpl30 chains. The rational for 
undertaking this is based on a series of converging obser- 
vations: (i) the prominent role of IL-6 in the pathogenesis 
of MM, (ii) the oncogenic activation of the Epo-R by a 
nonconservative point mutation [19], (iii) the increased 
binding affinity of the mutated forms of the GH-R for 
GH [21], (iv) the directed mutagenesis tudy by Yawata 
and coworkers showing the essential role of the ILdR& 
CRH domain in conveying the IL-6 signal. We therefore 
considered it important to test for the presence of poten- 
tially activating point mutations in both chains of the 
IL-6 receptor, and given the fact that the known activat- 
ing mutations all affected the CRH domain, we logically 
directed our first efforts at this region. Using total RNA 
as a template we analyzed by RT-PCR and SSCP a 
stretch of 638 bases divided between 5 overlapping am- 
plimers. None of the 28 tumors samples demonstrated a
reproducibly detectable mutated variant affecting this 
region of the gene. One might attribute this to a lack of 
sensitivity of the method. Although we cannot formally 
disprove this, we do not consider a technical problem 
could account for the present results. While analyzing 
this portion of the IL-6Ra gene, we detected mutated 
variants which upon verification corresponded to muta- 
tions introduced by either the reverse transcriptase or the 
Taq polymerase. We therefore considered these polym- 
erase artifacts as positive controls for our assay. The lack 
of mutations in the IL-6Ra gene cannot be explained by 
the patient population studied. Indeed, all 19 patients 
had an active form of the disease, and 11 out of the 19 
had terminal fuhninant extramedullary disease, a stage 
of the disease in which frequent mutations of p53 and 
Ras genes are found [28-301. Other IL-6R abnormalities 
in myeloma cells could involve deregulated expression of 
the protein. This was demonstrated by upregulated IL- 
6R gene expression achieved by insertion of intracister- 
nal particles into the IL-6R gene in a murine plasmacy- 
toma cell line [31]. Once the promoter and regulating 
regions of the IL-6R gene are known, it will be of interest 
to search for mutations in these regions in myeloma cells. 
We also studied the gp130 CRH domain, the exact 
function of which has not been clearly determined. How- 
ever, studies with other transducing chains of the haema- 
topoietic receptor family (G-CSF-R, EPO-R, GH-R, 
etc.) [19-21,231 strongly suggest hat this domain is es- 
sential for binding to the IL-6Rcx/IL-6 complex and 
dimerization of the gpl30 chain induced upon activation 
[32]. Interestingly, we detected polymorphism of the 
gp130 gene which was expressed at the RNA level both 
in patients with MM and healthy individuals. This poly- 
morphism was due first of all to a conservative substitu- 
tion at codon 122, and secondly to a point mutation in 
nucleotide 442 resulting in a non-conservative change of 
aa 148 from Arg to Leu. It would be of interest to deter- 
mine whether this latter polymorphic RNA is translated 
and to search for a change in the functional activity of 
the polymorphic gp130 protein. 
Finally, we investigated a cytoplasmic region of the 
gp130 that was shown to be sufficient o induce an IL-6- 
mediated signal. More recently, the Pro-X-Pro motif 
contained in this region was shown to be essential for 
association with a cytoplasmic tyrosine kinase [32]. We 
found point mutations in the gp130 cytoplasmic region 
in 2 out of 28 tumor samples. In the U266 cell line, 
mutation of the intracytoplasmic aa 710 converted Ser 
to Leu, and only the mutated allele was expressed. This 
sequence is different from the sequence initially reported 
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ACGT ACGT 
codon 
codon 
codon 692 
codon 678 
693 
Fig. 4. Sequence analysis of gp130 cytoplasmic band shifts. Sequences are shown 5’ (bottom) to 3’ (top). The codon at which a mutation 
indicated. The nucleotide sites of mutation are shown by underlined letters. Arrowheads point to bands corresponding to mutated bases. 
band shift sequence; (b) patient band shift sequence. 
occurs is 
(a) U266 
for U266 [14]. The cell line analyzed was effectively 
U266, since cells were producing IgEk It would be inter- 
esting to investigate whether this mutation has confered 
a selective growth advantage. In the freshly explanted 
tumor sample, 5 mutations were found, one conservative 
of the intracytoplasmic aa 711 and 4 non-conservative of 
the intracytoplasmic aa 678, 692, 693 and 705. In this 
case, both normal and mutated alleles were expressed. 
The presence of 40% non-tumor cells in the tumor sam- 
ple might explain why both normal and mutated alleles 
were expressed. Again, it would be of interest o investi- 
gate whether these mutations result in a change in gpl30 
functional activity. 
This study analyzed the gp130 CRH and cytoplasmic 
domains that have been identsed to date or are assumed 
to be essential for signal activation and transduction. As 
in the case of ILdR&, the unidentified promoter and 
regulating regions of the gp130 gene could be major 
targets of the oncogenic process. 
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